

Status: Currently Official on 14-Feb-2025
 Official Date: Official as of 01-May-2021
 Document Type: USP Monographs
 DocId: GUID-E298C921-ED7D-4870-A92A-52934B27D3E9_2_en-US
 DOI: https://doi.org/10.31003/USPNF_M17875_02_01
 DOI Ref: k89nv

© 2025 USPC
 Do not distribute

Ciprofloxacin Ophthalmic Ointment

DEFINITION

Ciprofloxacin Ophthalmic Ointment contains an amount of Ciprofloxacin Hydrochloride equivalent to NLT 90.0% and NMT 110.0% of the labeled amount of ciprofloxacin ($C_{17}H_{18}FN_3O_3$).

IDENTIFICATION

• **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

Add the following:

▲• **B.** The UV spectrum of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.▲ (USP 1-May-2021)

ASSAY

Change to read:

• PROCEDURE

▲**Solution A:** 0.29% (v/v) [phosphoric acid](#) in [water](#) prepared as follows. Transfer an appropriate volume of [phosphoric acid](#) to a suitable volumetric flask containing 90% of the final volume of water. Adjust with [triethylamine](#) to a pH of 5.2 and dilute with [water](#) to volume.

Mobile phase: [Acetonitrile](#) and *Solution A* (12:88)

Diluent: [Acetonitrile](#) and *Solution A* (13:87)

Standard solution: 0.1 mg/mL of [USP Ciprofloxacin Hydrochloride RS](#) in *Diluent*

Sample solution: Nominally 0.1 mg/mL of ciprofloxacin prepared as follows. Transfer an amount nominally equivalent to 2.5 mg of ciprofloxacin from Ophthalmic Ointment to a suitable volumetric flask. Add 15 mL of [hexane](#), and shake vigorously until the Ophthalmic Ointment is dispersed. Heat in a water bath at 60° for 30 min, with shaking. Add 25.0 mL of *Diluent*, while still warm, and shake vigorously for NLT 3 min. Allow the layers to separate, and use the lower, aqueous layer.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 278 nm. For *Identification B*, use a diode array detector in the range of 200–400 nm.

Column: 4.6-mm × 25-cm; 5-μm packing [L1](#)

Temperatures

Autosampler: 4°

Column: 39°

Flow rate: 1 mL/min

Injection volume: 20 μL

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0%▲ (USP 1-May-2021)

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of ciprofloxacin ($C_{17}H_{18}FN_3O_3$) in the portion of Ophthalmic Ointment taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

r_U = peak response ▲ of ciprofloxacin▲ (USP 1-May-2021) from the *Sample solution*

r_s = peak response [▲]of ciprofloxacin [▲](USP 1-May-2021) from the *Standard solution*

C_s = concentration of [USP Ciprofloxacin Hydrochloride RS](#) in the *Standard solution* (mg/mL)

C_u = nominal concentration of ciprofloxacin in the *Sample solution* (mg/mL)

M_{r1} = molecular weight of ciprofloxacin, 331.34

M_{r2} = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81

Acceptance criteria: 90.0%–110.0%

IMPURITIES

Add the following:

▲ • ORGANIC IMPURITIES

Solution A, Mobile phase, Diluent, and Chromatographic system: Proceed as directed in the Assay.

System suitability solution: 0.002 mg/mL each of [USP Ciprofloxacin Hydrochloride RS](#) and [USP Ciprofloxacin Ethylenediamine Analog RS](#) in *Diluent*

Sensitivity solution: 0.2 µg/mL of [USP Ciprofloxacin Hydrochloride RS](#) in *Diluent*

Standard solution: 0.001 mg/mL of [USP Ciprofloxacin Hydrochloride RS](#) in *Diluent*

Sample solution: Nominally 0.2 mg/mL of ciprofloxacin prepared as follows. Transfer an amount nominally equivalent to 5 mg of ciprofloxacin from Ophthalmic Ointment to a suitable volumetric flask. Add 15 mL of [hexane](#), and shake vigorously until the Ophthalmic Ointment is dispersed. Heat in a water bath at 60° for 30 min, with shaking. Add 25.0 mL of *Diluent*, while still warm, and shake vigorously for NLT 3 min. Allow the layers to separate, and use the lower, aqueous layer.

System suitability

Samples: *System suitability solution, Sensitivity solution, and Standard solution*

Suitability requirements

Resolution: NLT 6.0 between ciprofloxacin ethylenediamine analog and ciprofloxacin, *System suitability solution*

Relative standard deviation: NMT 5.0% for ciprofloxacin, *Standard solution*

Signal-to-noise ratio: NLT 10, *Sensitivity solution*

Analysis

Samples: *Standard solution and Sample solution*

Calculate the percentage of each impurity in the portion of Ophthalmic Ointment taken:

Result = $(r_u/r_s) \times (C_s/C_u) \times (1/F) \times 100$

r_u = peak response of each impurity from the *Sample solution*

r_s = peak response of ciprofloxacin from the *Standard solution*

C_s = concentration of [USP Ciprofloxacin Hydrochloride RS](#) in the *Standard solution* (mg/mL)

C_u = nominal concentration of ciprofloxacin in the *Sample solution* (mg/mL)

F = relative response factor (see [Table 1](#))

Acceptance criteria: See [Table 1](#).

Table 1

Name	Relative Retention Time	Relative Response Factor ^a	Acceptance Criteria, NMT (%)
Ciprofloxacin ethylenediamine analog	0.7	1.35	0.2
Ciprofloxacin	1.0	—	—
Any unspecified impurity	—	1.0	0.1